---
title: "Sana Biotechnology, Inc. (SANA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SANA.US.md"
symbol: "SANA.US"
name: "Sana Biotechnology, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T03:06:43.425Z"
locales:
  - [en](https://longbridge.com/en/quote/SANA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SANA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SANA.US.md)
---

# Sana Biotechnology, Inc. (SANA.US)

## Company Overview

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.sana.com](https://www.sana.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.52 | 326 | - | - | - |
| PB | 7.14 | 373 | 6.95 | 5.69 | 4.59 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 2 | 20% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.06 |
| Highest Target | 12.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SANA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SANA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SANA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SANA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**